Omnimodus Elixir Kft.
- Address
- Fecske Utca 10, 9200 Mosonmagyaróvár, Hungary
Omnimodus Elixir Kft. - Respiratory Disease Research Center
Omnimodus Elixir Kft. is a specialized clinical research center dedicated to advancing therapeutic interventions for respiratory diseases. The facility demonstrates extensive expertise in conducting pivotal Phase 3 trials for both chronic obstructive pulmonary disease (COPD) and asthma, with particular focus on novel biologics and innovative drug delivery systems. The center plays a crucial role in evaluating emerging treatments that address unmet needs in respiratory medicine, from exacerbation prevention to long-term disease management.
- Chronic Obstructive Pulmonary Disease (COPD) therapeutic trials, including biologics like itepekimab and tozorakimab for moderate-to-severe disease
- Asthma research across disease severity spectrum, evaluating novel monoclonal antibodies and long-term prevention strategies
- Innovative drug delivery systems and propellant formulations for inhaled medications
- Refractory chronic cough investigations and specialized respiratory symptom management
The research center excels in conducting long-term safety and efficacy studies, with expertise in evaluating lung function outcomes, exacerbation rates, and quality of life measures. Their portfolio includes comprehensive assessments of next-generation biologics such as amlitelimab, lunsekimig, and dupilumab, as well as comparative studies of inhaled therapies. The facility's capability to conduct both controlled efficacy trials and open-label extension studies demonstrates their commitment to understanding the full therapeutic profile of respiratory medications from initial proof-of-concept through long-term real-world application.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Omnimodus Elixir Kft.
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) | AstraZeneca AB | Phase III | Not Recruiting | Apr 2023 | May 2026 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 3 | Unknown | 2023-04-20 | 2024-06-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.